Sylvain Durrleman

3.3k total citations · 1 hit paper
16 papers, 2.5k citations indexed

About

Sylvain Durrleman is a scholar working on Statistics and Probability, Economics and Econometrics and Oncology. According to data from OpenAlex, Sylvain Durrleman has authored 16 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Statistics and Probability, 5 papers in Economics and Econometrics and 4 papers in Oncology. Recurrent topics in Sylvain Durrleman's work include Statistical Methods in Clinical Trials (8 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers) and Optimal Experimental Design Methods (3 papers). Sylvain Durrleman is often cited by papers focused on Statistical Methods in Clinical Trials (8 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers) and Optimal Experimental Design Methods (3 papers). Sylvain Durrleman collaborates with scholars based in United States, France and Netherlands. Sylvain Durrleman's co-authors include Richard Simon, Annick Alpérovitch, Richard H. Simon, P. Nigel Leigh, Gilbert Bensimon, Philippe Guillet, Jean-Christophe Delumeau, Vincent Meininger, Lucette Lacomblez and Philip Chaikin and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Biometrics.

In The Last Decade

Sylvain Durrleman

16 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Flexible regression models with cubic splines

1989 2.1k citations Sylvain Durrleman, Richard Simon Statistics in Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sylvain Durrleman United States	11	415	358	325	262	250	16	2.5k
Hubert J. A. Schouten Netherlands	28	161 0.4×	221 0.6×	510 1.6×	139 0.5×	327 1.3×	62	2.9k
Laura Antolini Italy	26	355 0.9×	265 0.7×	290 0.9×	173 0.7×	355 1.4×	120	2.3k
C. Ralph Buncher United States	32	381 0.9×	196 0.5×	248 0.8×	262 1.0×	236 0.9×	89	3.4k
Kristan A. L'Abbé Canada	11	296 0.7×	246 0.7×	287 0.9×	218 0.8×	140 0.6×	15	2.2k
Varghese George United States	26	235 0.6×	153 0.4×	276 0.8×	294 1.1×	289 1.2×	88	2.6k
Cristina Sison United States	32	309 0.7×	228 0.6×	313 1.0×	285 1.1×	289 1.2×	123	3.4k
V. Gallo United Kingdom	26	354 0.9×	229 0.6×	550 1.7×	442 1.7×	247 1.0×	80	4.0k
Wei Yann Tsai United States	34	351 0.8×	1.1k 3.2×	283 0.9×	334 1.3×	220 0.9×	57	4.3k
William D. Finkle United States	14	295 0.7×	278 0.8×	205 0.6×	143 0.5×	138 0.6×	22	2.7k
Amalia Karahalios Australia	24	316 0.8×	307 0.9×	287 0.9×	247 0.9×	131 0.5×	104	1.8k

Countries citing papers authored by Sylvain Durrleman

Since Specialization

Citations

This map shows the geographic impact of Sylvain Durrleman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvain Durrleman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvain Durrleman more than expected).

Fields of papers citing papers by Sylvain Durrleman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvain Durrleman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvain Durrleman. The network helps show where Sylvain Durrleman may publish in the future.

Co-authorship network of co-authors of Sylvain Durrleman

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvain Durrleman. A scholar is included among the top collaborators of Sylvain Durrleman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvain Durrleman. Sylvain Durrleman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Shun, Zhenming, et al.. (2005). Statistical consideration of the strategy for demonstrating clinical evidence of effectiveness—one larger vs two smaller pivotal studies Statistics in Medicine 2005; 24:1619–1637. Statistics in Medicine. 24(11). 1652–1656. 2 indexed citations

Girard, Pascal, Pascal Girard, Michel Cucherat, et al.. (2004). Simulation des essais cliniques dans le développement des médicaments. Therapies. 59(3). 287–295. 10 indexed citations

Girard, Pascal, Pascal Girard, Michel Cucherat, et al.. (2004). Clinical Trial Simulation in Drug Development. Therapies. 59(3). 297–304. 12 indexed citations

Shun, Zhenming, et al.. (2004). Statistical consideration of the strategy for demonstrating clinical evidence of effectiveness—one larger vs two smaller pivotal studies. Statistics in Medicine. 24(11). 1619–1637. 17 indexed citations

Alexandre, J M, Éric Abadie, Daniel Brasseur, et al.. (2003). Study Design in Osteoporosis: A European Perspective. Journal of Bone and Mineral Research. 18(6). 1133–1138. 17 indexed citations

Durrleman, Sylvain & Philip Chaikin. (2003). The use of putative placebo in active control trials: two applications in a regulatory setting. Statistics in Medicine. 22(6). 941–952. 28 indexed citations

Chaikin, Philip, et al.. (2000). Insourcing International Clinical Trials to Affiliates: A Business-Driven and Medically Sound Strategy. Drug Information Journal. 34(4). 1293–1301. 1 indexed citations

Lacomblez, Lucette, Gilbert Bensimon, P. Nigel Leigh, et al.. (1996). A confirmatory dose-ranging study of riluzole in ALS. Neurology. 47(6_suppl_4). S242–50. 151 indexed citations

Boutitie, Florent, et al.. (1993). [Monitoring of clinical trials and interim analysis. 1. Monitoring committee].. PubMed. 47(4). 345–9. 3 indexed citations

10.

Boutitie, Florent, et al.. (1993). [Monitoring of clinical trials and interim analysis. 2. Statistic methods].. PubMed. 47(4). 351–5. 1 indexed citations

11.

Durrleman, Sylvain & Richard Simon. (1991). When to randomize?. Journal of Clinical Oncology. 9(1). 116–122. 10 indexed citations

12.

Simon, Richard, Sylvain Durrleman, Richard T. Hoppe, et al.. (1990). Prognostic factors for patients with diffuse large cell or immunoblastic non‐Hodgkin's lymphomas: Experience of the non‐Hodgkin's lymphoma pathologic classification project. Medical and Pediatric Oncology. 18(2). 89–96. 11 indexed citations

13.

Durrleman, Sylvain & Richard H. Simon. (1990). Planning and Monitoring of Equivalence Studies. Biometrics. 46(2). 329–329. 62 indexed citations

14.

Durrleman, Sylvain & Annick Alpérovitch. (1989). Increasing trend of ALS in France and elsewhere. Neurology. 39(6). 768–768. 73 indexed citations

15.

Durrleman, Sylvain, Jean L. Grem, & Bruce D. Cheson. (1989). 2‘‐deocycoformycin after failure of alpha‐interferon in hairy cell leukemia. European Journal Of Haematology. 43(4). 297–302. 6 indexed citations

16.

Durrleman, Sylvain & Richard Simon. (1989). Flexible regression models with cubic splines. Statistics in Medicine. 8(5). 551–561. 2096 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact